![Tyrell J. Rivers](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tyrell J. Rivers
Director/Board Member at
CELLECTIS S.A.
Profile
Tyrell J.
Rivers is currently Director at Cerapedics, Inc., ADC Therapeutics SA (Independent Non-Executive Director since 2018), Corvidia Therapeutics, Inc., Cellectis SA (Director since 2024), Quell Therapeutics Ltd., Fuse Biotherapeutics, Inc., Nucleus Radiopharma, Inc., and SixPeaks Bio AG.
Former roles include Director at PhaseBio Pharmaceuticals, Inc. in 2018; Executive Director-Corporate Development at AstraZeneca PLC; Director at VaxEquity Ltd. and Armaron Bio Ltd.; Independent Director at G1 Therapeutics, Inc. from 2017 to 2018; Independent Director at Viela Bio, Inc. from 2018 to 2021; Director at Biohealth Innovation, Inc. from 2022 to 2024; Director at Goldfinch Bio, Inc. from 2021 to 2022; and Senior Associate at MedImmune Ventures, Inc. from 2009 to 2014.
Education includes undergraduate studies at Massachusetts Institute of Technology, graduate and doctorate degrees from The University of Texas at Austin, and an MBA from The Leonard N Stern School of Business.
Tyrell J. Rivers active positions
| Companies | Position | Start |
|---|---|---|
| ADC THERAPEUTICS SA | Director/Board Member | 2018-05-31 |
| CELLECTIS S.A. | Director/Board Member | 2024-05-05 |
Cerapedics, Inc.
 Cerapedics, Inc. Medical/Nursing ServicesHealth Services Operates as an orthopedics company that develops bone repair products | Director/Board Member | - |
Nucleus Radiopharma, Inc.
 Nucleus Radiopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a end-to-end contract development and manufacturing organization | Director/Board Member | - |
Fuse Biotherapeutics, Inc.
 Fuse Biotherapeutics, Inc. BiotechnologyHealth Technology Develops transformative immune modulating therapeutics for patients with cancer | Director/Board Member | - |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops and supplies immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases | Director/Board Member | - |
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Develops precision cardiovascular therapies | Director/Board Member | - |
SixPeaks Bio AG
 SixPeaks Bio AG Pharmaceuticals: MajorHealth Technology Develops pipeline medicines for healthy weight loss | Director/Board Member | - |
Former positions of Tyrell J. Rivers
| Companies | Position | End |
|---|---|---|
Biohealth Innovation, Inc.
 Biohealth Innovation, Inc. Financial ConglomeratesFinance Sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth | Director/Board Member | 2023-12-31 |
| ░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Tyrell J. Rivers
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
40
1st degree connections
20
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 20 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
PhaseBio Pharmaceuticals, Inc.
 PhaseBio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapies for cardiovascular diseases | Health Technology |
MedImmune Ventures, Inc.
 MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures invests in private biotechnology companies located across the globe primarily in North America. The firm focuses on healthcare sectors such as molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging and healthcare IT. The firm provides financing for seed, early, later and mezzanine stage capital requirements with an investment size ranging from USD 5 - USD 10 million per round. It acts as a lead investor and takes an active role on the board of directors. | Finance |
Cerapedics, Inc.
Cerapedics, Inc. Medical/Nursing ServicesHealth Services Operates as an orthopedics company that develops bone repair products | Health Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
The University of Texas at Austin
 The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cellectis SA
 Cellectis SA Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops immunotherapies | Health Technology |
Armaron Bio Ltd.
 Armaron Bio Ltd. Electronic Equipment/InstrumentsElectronic Technology Develops cardioprotection and neuroprotection small molecules to reduce tissue damage for heart attacks | Electronic Technology |
ADC Therapeutics SA
 ADC Therapeutics SA Pharmaceuticals: MajorHealth Technology Develops proprietary antibody drug conjugates for the treatment of both solid and hematological cancers | Health Technology |
G1 Therapeutics, Inc.
 G1 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cancer treatment | Health Technology |
Biohealth Innovation, Inc.
Biohealth Innovation, Inc. Financial ConglomeratesFinance Sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth | Finance |
The Leonard N Stern School of Business
 The Leonard N Stern School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Develops precision cardiovascular therapies | Health Technology |
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Develop medicines and therapies for patients with kidney disease | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company that develops treatments for inflammation and autoimmune diseases | Health Technology |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops and supplies immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases | Health Technology |
VaxEquity Ltd.
 VaxEquity Ltd. BiotechnologyHealth Technology Develops saRNA vaccines platform technology | Health Technology |
Fuse Biotherapeutics, Inc.
Fuse Biotherapeutics, Inc. BiotechnologyHealth Technology Develops transformative immune modulating therapeutics for patients with cancer | Health Technology |
Nucleus Radiopharma, Inc.
Nucleus Radiopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a end-to-end contract development and manufacturing organization | Health Technology |
SixPeaks Bio AG
SixPeaks Bio AG Pharmaceuticals: MajorHealth Technology Develops pipeline medicines for healthy weight loss | Health Technology |
- Stock Market
- Insiders
- Tyrell J. Rivers
